This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
asthma
Asthma
Chronic airway hyperresponsiveness from Th2/ILC2 cytokines (IL-4, IL-5, IL-13), mast cell, and eosinophil activation; reversible bronchoconstriction and airway remodeling. ICS are first-line; dupilumab, mepolizumab, and omalizumab for severe type 2 asthma.
Entry Metadata
| Field | Value |
|---|---|
| ID | asthma |
| Name | Asthma |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Am J Respir Crit Care Med. 2022;205(1):17-35. · PubMed 34665667
- Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716-725. · PubMed 22561835
- Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;379(26):2486-2496. · PubMed 30088505